SAN DIEGO, CA / ACCESSWIRE / July 7, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (INNV) announced today it has entered into an exclusive license and distribution agreement with Elis Pharmaceuticals, Ltd. ("Elis"). Pursuant to the agreement, Innovus Pharma granted to Elis an exclusive license to market and sell Innovus Pharma's products in Turkey and select African and Gulf countries. Under the agreement, Innovus Pharma is eligible to receive up to $35.5 million dollars in sales milestone payments plus an agreed-upon transfer price.
Bassam Damaj, President and Chief Executive Officer of Innovus Pharma commented, "We are very excited about this major commercial partnership collaboration with Elis for our products. We believe that these types of products are in high demand in these countries and are expected by Elis Pharma to be very competitive as the "first in class product" in their fields in these regions. This partnership is the ninth commercial partnership for the Company and its products.Our goal for 2015 was to sign commercial partnerships for the sale of our products in 40 additional countries and I am pleased to announce that with this partnership we are in over 60 countries therefore exceeding our goal by 50% half-way through 2015."
"We are proud that Innovus has signed 9 commercial partnerships for the potential sale of our products in over 60 countries and is eligible to receive over $480 million in potential sales milestones from its partners plus either double digit royalties or pre-agreed transfer prices," added Reuven Rubinson, Vice President of Finance of Innovus Pharma.
"We are very excited about this partnership and especially about Innovus Pharma's unique and innovative products. Elis Pharma has over 1,000 products in this region. We look forward to getting the required government approvals and launch the products in the licensed territories in the near future," said Mr. Rashed Assouma, CEO of Elis Pharmaceuticals.
The products included are
1) Zestra(R) for increasing arousal and desire in women which is currently commercialized in the US and in Canada by Orimed Pharma, in the United Kingdom by Tramorgan, Morocco and the United Arab Emirates ("UAE") by Sothema Labs, and select European countries by Danalife, is
2) EjectDelay(R) for treating premature ejaculation which is currently commercialized in the U.S. by Innovus and expected to be launched in Canada under the name "Uxor(TM)" by Orimed Pharma in August 2015 and
3) Sensum+(R) for increasing penile sensitivity is currently commercialized in the U.S. and the UK by Tramorgan and in Morocco by Ovation Pharma. Vesele(R) for increasing sexual and cognitive health is currently commercialized in the U.S. and in the U.K. by Tramorgan. Zestra Glide(R) is currently commercialized in the U.S., in Canada by Orimed Pharma, in Morocco and the UAE by Sothema Labs.
About Zestra(R) and FSI/AD
Zestra(R) is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra(R) is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.
About EjectDelay(R) and Premature Ejaculation
EjectDelay(R) is an over-the-counter ("OTC") U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for treatment of premature ejaculation. The drug typically works within minutes of application to the glans. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes. For more information visit www.ejectdelay.com.
Premature ejaculation ("PE") is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman state,"Global studies consistently report that 20-30% of men experience PE worldwide. This means that PE is experienced at similar rates across the globe."
Sensum+ is a blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+ (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+ was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+ twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter.For more information visit www.sensumplus.com.
Reduced Penile Sensitivity ("RPS") results from a gradual loss of sensitivity over time. As a person ages, the dulling effect can increase. RPS can happen at any age and its prevalence is consistent across all ages. RPS results from many causes, including diabetes, ilioinguinal nerve entrapment resulting in 20% of all hernia surgeries a year, circumcision, multiple sclerosis patients, and 2% of patients using anti-depressants drugs.
Vesele(R) is a proprietary, novel oral dietary supplement to maximize nitric oxide's beneficial effects on sexual function and brain health. Vesele(R) contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine(R).
The beneficial effects of Vesele(R) on sexual and cognitive functions were confirmed in a four-month US clinical survey study involving 152 patients (69 men and 83 women). Results from the clinical survey have indicated (1) improvement of hardness and maintenance in men and increased sexual intercourse frequency with their partners and (2) increase in lubrication in women, when taken separately by each. Positive effects on brain health were translated by an increase in recall of words and names. For more information visit www.myvesele.com
Elis Pharmaceuticals markets and distributes over 1,000 branded and generic pharmaceuticals and under-licensed products. Established in the United Arab Emirates, Elis Pharmaceuticals' fast growth has allowed it to become a global company, with a strong focus on the Middle East and North Africa and Turkey. The Company serves over 40markets and has strengthened its presence by collaborating with multinational companies.
For more information, visit Elis Pharma's website at www.elispharmaceuticals.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health,vitality and respiratory diseases. The Company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health and two products in the pipeline including, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare(TM) OTC for Allergic Rhinitis if approved by the FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products (Zestra(R), Zestra Glide(R), EjectDelay(R), Sensum+(R) and Vesele(R)) and to achieve its other development, commercialization and financial goals, whether Elis will continue to successfully market and sell our products in its licensed territory,and whether Innovus Pharma will receive milestone payments from such sales. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Innovus Pharma Contact:
Vice President of Finance
Elis Pharma Contact
Chief Executive Officer
T:+971 554 583 025
SOURCE: Innovus Pharmaceuticals, Inc.